Just prior to JP Morgan in 2015, Novartis and Qualcomm launched dRx Capital to find and to fund new ventures that can develop technology to aid both companies. General Partner Carolyne Zimmerman, a former Novartis executive, explains how dRx’s partners are looking for early-stage opportunities in Digital Health companies.
Carolyne Zimmerman is a general partner at dRx Capital, and she also serves as a senior transaction leader in the Global BD&L Group at Novartis Pharmaceuticals.
Prior to assuming these roles in the digital medicine space, Carolyne led the business development and licensing efforts for the Global Cardio-Metabolic Business Franchise where she was responsible for securing strategic assets to expand the portfolio. In this role she worked closely with the franchise medical and marketing leadership teams to shape and implement licensing and acquisition strategy to enable Novartis to continue to deliver novel therapies to address unmet medical needs and improve patient care and outcomes.
During her career at Novartis, Carolyne has held leadership roles in the three pillars of business development and licensing: search and evaluation, negotiations, and alliance management. Her broad transactional experience includes negotiating licenses, collaborations, acquisitions, divestments, restructurings, and option deals as well as managing complex alliances with both biotech and big pharma companies. Prior to Novartis, Carolyne worked in business development functions in the drug delivery and pharmaceutical process technology arena.
Carolyne holds a bachelor of science in engineering sciences from the University of California, San Diego and an MBA from Columbia Business School.